Evelo Bioscience News Today

Evelo Biosciences shares have tumbled 46% in premarket trading after the biotech firm revealed disappointing results in a phase II psoriasis trial for its...

The Entire Business World on a Single Page with the Web's Most Comprehensive One-Stop Finance News Hub.

Evelo Biosciences, Inc. (NASDAQ:EVLO – Get Rating) – Analysts at Cantor Fitzgerald decreased their FY2023 earnings estimates for Evelo Biosciences in a report issued on Wednesday, May 17th. Cantor Fitzgerald analyst K. Kluska now forecasts that the company will post earnings per share of ($0.58) for the year, down from their prior estimate of ($0.45). […]

Vallon Pharmaceuticals (NASDAQ:VLON – Get Rating) and Evelo Biosciences (NASDAQ:EVLO – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings. Valuation & Earnings This table compares Vallon Pharmaceuticals and […]

Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.

​​​​​​​The 2022 American Academy of Dermatology Annual Meeting saw several milestones for treatment explorations for inflammatory diseases. Here is some of the major news:

EVLO earnings call for the period ending December 31, 2021.

Equities analysts forecast that Evelo Biosciences, Inc. (NASDAQ:EVLO – Get Rating) will announce earnings of ($0.57) per share for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Evelo Biosciences’ earnings, with the lowest EPS estimate coming in at ($0.63) and the highest estimate coming in at ($0.50). Evelo Biosciences posted […]

Ultragenyx (RARE) and GeneTx Biotherapeutics dose the first patient in a phase I/II study on GTX-102 for treating patients with Angelman syndrome in Canada.